Real World Treatment Patterns in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Switching from First Line Ibrutinib to Acalabrutinib
Jacobs, Ryan, Wang, Ruibin, He, Jinghua, Lu, Xiaoxiao, Wu, Linda, Khan, Wasiulla, Qureshi, Zaina P., Levy, Moshe Yair
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Tailor: Interventional Study Evaluating Physician's Choice of Ibrutinib Monotherapy or Ibrutinib-Venetoclax Combination Using Dose Modifications and Alternate Dosing Approaches in Patients with Untreated Chronic Lymphocytic Leukemia
Sharman, Jeff P., Burger, Jan A., Barrientos, Jacqueline, Kuruvilla, Philip, Patel, Sima, Krigsfeld, Gabriel, Srikanthan, Sowmya, Messahel, Bothayna, Khan, Wasiulla, Smith, Emma, Ghia, Paolo
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib
Jacobs, Ryan, Lu, Xiaoxiao, Emond, Bruno, Morrison, Laura, Kinkead, Frédéric, Lefebvre, Patrick, Lafeuille, Marie-Hélène, Khan, Wasiulla, Wu, Linda, Qureshi, Zaina P., Levy, Moshe Yair
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION
Breccia, Massimo, Mauro, Michael J., Jabbour, Elias, Saglio, Giuseppe, Jiménez-Velasco, Antonio, le Coutre, Philipp D, DeGutis, Irene, Khan, Wasiulla, Sy, Oumar, Swanink, Rene, Cortes, Jorge E.
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article
Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study
Mauro, Michael J., Oehler, Vivian G., Thompson, James E., McCloskey, James K., Heinrich, Michael C., Dakhil, Shaker R., DeGutis, Irene, Tabano, David, Khan, Wasiulla, Moslehi, Javid J.
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article
Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib
Jacobs, Ryan, Lu, Xiaoxiao, Emond, Bruno, Morrison, Laura, Kinkead, Frederic, Lefebvre, Patrick, Lafeuille, Marie-Hélène, Khan, Wasiulla, Wu, Linda H, Qureshi, Zaina P, Levy, Moshe Yair
Published in Future oncology (London, England) (01.01.2024)
Published in Future oncology (London, England) (01.01.2024)
Get full text
Journal Article
Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry
Ghosh, Nilanjan, Sharman, Jeff P., Gutierrez, Meghan, Khan, Wasiulla, Qureshi, Zaina P., Raz, Anat, Girardi, Vincent, Krigsfeld, Gabriel S., Barrientos, Jacqueline C.
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Get full text
Journal Article
CML-081: Effect of Comorbidities on Response Outcomes with First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION
Breccia, Massimo, Mauro, Michael, Jabbour, Elias, Saglio, Giuseppe, Jiménez-Velasco, Antonio, Coutre, Philipp le, DeGutis, Irene, Khan, Wasiulla, Sy, Oumar, Swanink, Rene, Cortes, Jorge E.
Published in Clinical lymphoma, myeloma and leukemia (01.09.2021)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2021)
Get full text
Journal Article
Poster: CML-081: Effect of Comorbidities on Response Outcomes With First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION
Breccia, Massimo, Mauro, Michael, Jabbour, Elias, Saglio, Giuseppe, Jiménez-Velasco, Antonio, Coutre, Philipp le, DeGutis, Irene, Khan, Wasiulla, Sy, Oumar, Swanink, Rene, Cortes, Jorge E.
Published in Clinical lymphoma, myeloma and leukemia (01.09.2021)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2021)
Get full text
Journal Article
Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
Lu, Xiaoxiao, Emond, Bruno, Morrison, Laura, Kinkead, Frederic, Lefebvre, Patrick, Lafeuille, Marie-Helene, Khan, Wasiulla, Wu, Linda H, Qureshi, Zaina P, Jacobs, Ryan
Published in Patient preference and adherence (30.09.2023)
Published in Patient preference and adherence (30.09.2023)
Get full text
Journal Article